Inhibikase Therapeutics, Inc.

NasdaqCM:IKT Stock Report

Market Cap: US$215.7m

Inhibikase Therapeutics Future Growth

Future criteria checks 0/6

Inhibikase Therapeutics is forecast to grow earnings and revenue by 37% and 67.2% per annum respectively while EPS is expected to grow by 54.8% per annum.

Key information

37.0%

Earnings growth rate

54.8%

EPS growth rate

Biotechs earnings growth26.7%
Revenue growth rate67.2%
Future return on equityn/a
Analyst coverage

Low

Last updated15 Nov 2024

Recent future growth updates

Recent updates

Can Inhibikase Therapeutics (NASDAQ:IKT) Afford To Invest In Growth?

Jan 25
Can Inhibikase Therapeutics (NASDAQ:IKT) Afford To Invest In Growth?

Inhibikase stock rises 12% on FDA nod to start study of IkT-001Pro for leukemia

Aug 26

Inhibikase Therapeutics GAAP EPS of -$0.18, revenue of $6.55M

Aug 12

Will Inhibikase Therapeutics (NASDAQ:IKT) Spend Its Cash Wisely?

Aug 09
Will Inhibikase Therapeutics (NASDAQ:IKT) Spend Its Cash Wisely?

Here's Why We're Watching Inhibikase Therapeutics' (NASDAQ:IKT) Cash Burn Situation

Apr 06
Here's Why We're Watching Inhibikase Therapeutics' (NASDAQ:IKT) Cash Burn Situation

Earnings and Revenue Growth Forecasts

NasdaqCM:IKT - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20279-52N/A-643
12/31/2026N/A-45N/A-433
12/31/2025N/A-34N/A-303
12/31/2024N/A-22N/A-203
9/30/20240-20-17-17N/A
6/30/20240-18-16-16N/A
3/31/20240-19-16-16N/A
12/31/20230-19-18-18N/A
9/30/20230-19-18-18N/A
6/30/20230-19-20-20N/A
3/31/20230-18-20-19N/A
12/31/20220-18-18-17N/A
9/30/20220-19-18-18N/A
6/30/20220-19-14-14N/A
3/31/20222-17-14-14N/A
12/31/20213-15-14-14N/A
9/30/20213-11-11-11N/A
6/30/20213-7-9-9N/A
3/31/20212-5-5-5N/A
12/31/20201-3-1-1N/A
9/30/20201-200N/A
6/30/20201-300N/A
3/31/20201-500N/A
12/31/20191-600N/A
9/30/20192-711N/A
3/31/20194-400N/A
12/31/20184-211N/A
9/30/20183-100N/A
3/31/201830N/A0N/A
12/31/201720N/A0N/A
12/31/20161-1N/A0N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IKT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IKT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IKT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IKT is forecast to have no revenue next year.

High Growth Revenue: IKT is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if IKT's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 15:44
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Inhibikase Therapeutics, Inc. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WhiteH.C. Wainwright & Co.
Yuchen DingJefferies LLC
Jason McCarthyMaxim Group